Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 1341Glioblastoma 493Gliosarcoma 470Osteosarcoma 364Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 252Neoplasms 231Glioma 230Lymphoma 227Rhabdomyosarcoma 209Neuroblastoma 209Breast Neoplasms 205Sarcoma, Ewing 203Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 183Ovarian Neoplasms 177Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 169Lymphoma, Follicular 158Liposarcoma 144Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Adenocarcinoma × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡